The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CDXS | -59.57% | -88.34% | -34.91% | -87% |
| S&P | +12.65% | +91.73% | +13.89% | +457% |
Codexis, Inc. is an enzyme engineering company, which engages in the development and sale of therapeutics. It operates through the Performance Enzymes and Novel Biotherapeutics segments. The Performance Enzymes segment commercializes CodeEvolver protein engineering technology platform and products in the pharmaceuticals market. The Novel Biotherapeutics segment targets new opportunities to discover and improve biotherapeutic drug candidates. Its products include screening kits and Codex HiFi Hot Start DNA Polymerase. The company was founded in January 2002 and is headquartered in Redwood City, CA.
Codexis is leveraging its core technology to create more effective life science tools.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $8.60M | -33.0% |
| Gross Profit | $4.82M | -34.3% |
| Gross Margin | 56.02% | -1.1% |
| Market Cap | $220.25M | 0.8% |
| Market Cap / Employee | $1.17M | 0.0% |
| Employees | 188 | 8.0% |
| Net Income | -$19.62M | 5.0% |
| EBITDA | -$16.89M | -15.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $25.84M | -31.9% |
| Accounts Receivable | $9.73M | -41.2% |
| Inventory | 1.9 | -7.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $65.53M | 73.5% |
| Short Term Debt | $3.09M | -24.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -47.00% | -6.0% |
| Return On Invested Capital | -34.16% | -8.7% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$7.89M | 43.6% |
| Operating Free Cash Flow | -$7.70M | 40.7% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 5.29 | 3.29 | 4.07 | 3.96 | 15.93% |
| Price to Sales | 6.53 | 4.45 | 3.64 | 4.16 | 20.85% |
| Price to Tangible Book Value | 5.47 | 3.42 | 4.29 | 4.14 | 17.23% |
| Enterprise Value to EBITDA | -71.19 | -11.89 | -19.43 | -13.59 | 14.53% |
| Return on Equity | -85.0% | -115.5% | -111.0% | -114.3% | 51.72% |
| Total Debt | $59.90M | $59.50M | $68.98M | $68.62M | 63.98% |
No podcast episodes available.
CDXS earnings call for the period ending September 30, 2021.
CDXS earnings call for the period ending March 31, 2020.
CDXS earnings call for the period ending December 31, 2019.
CDXS earnings call for the period ending September 30, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
